Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1738-1743, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ali, A. C. Y.
Right arrow Articles by Campbell, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ali, A. C. Y.
Right arrow Articles by Campbell, J. A.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Drug Monitoring and Toxicology
Right arrow Hematology
Right arrow Oak Ridge Conference
(Clinical Chemistry. 1997;43:1738-1743.)
© 1997 American Association for Clinical Chemistry, Inc.

Oak Ridge Conference

Interferences of o-raffinose cross-linked hemoglobin in three methods for serum creatinine

Arlene C. Y. Alia, Chrystina C. Mihas and Janet A. Campbell

a Author for correspondence: fax 416-798-0152.


Abstract

The interferences of o-raffinose cross-linked hemoglobin (HemolinkTM) were examined and compared in two serum creatinine methods on the Hitachi 717 [Boehringer Mannheim (BMC) and Synermed] and in an enzymatic creatinine method on the Vitros 750 (Johnson & Johnson). Interference was considered significant when the change in creatinine concentration from the control exceeded the 95% confidence limits of each method. Significant interference was observed for the BMC/Hitachi 717 method with Hemolink >=5 g/L. No interference was observed for the Synermed/Hitachi 717 assay with Hemolink up to 30 g/L in normal samples and up to 50 g/L in samples with increased creatinine. No interference was observed for the Vitros 750 assay with Hemolink up to 50 g/L at both normal and increased concentrations of creatinine. Although the BMC/Hitachi 717 method was considered unacceptable, the Synermed/Hitachi 717 and the Vitros 750 methods allow accurate quantification of serum creatinine in the presence of Hemolink.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
G. L. Myers, W. G. Miller, J. Coresh, J. Fleming, N. Greenberg, T. Greene, T. Hostetter, A. S. Levey, M. Panteghini, M. Welch, et al.
Recommendations for Improving Serum Creatinine Measurement: A Report from the Laboratory Working Group of the National Kidney Disease Education Program
Clin. Chem., January 1, 2006; 52(1): 5 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. A. Ali, G. S. Ali, J. M. Steinke, and A. P. Shepherd
Co-Oximetry Interference by Hemoglobin-Based Blood Substitutes
Anesth. Analg., April 1, 2001; 92(4): 863 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Balion, P. A. Champagne, and A. C. Y. Ali
Evaluation of HemogloBindTM for Removal of o-Raffinose Cross-Linked Hemoglobin (HemolinkTM) from Serum
Clin. Chem., September 1, 1997; 43(9): 1796 - 1798.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.